ArticleThe World Allergy Organization journal2025
Characterization of a major house dust mite allergen Der p 22 among Malaysian adult population.
Article in The World Allergy Organization journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comment on "Characterization of a major house dust mite allergen Der p 22 among Malaysian adult population".The World Allergy Organization journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: House dust mites (HDM) are a major trigger factor of allergic diseases worldwide. Objective: To characterize the group 22 allergen from the HDM Methods: Recombinant Der p 22 and 33 alanine mutants were expressed in Results: Recombinant Der p 22 was expressed and purified as a 17.2 kDa protein. Among 149 atopic Malaysian adults, 54% had detectable sIgE to Der p 22. IgE inhibition assays demonstrated partial cross-reactivity between Der p 22 and Der p 2. High-level group 22-specific IgE responses (Class 3+) were associated with an increased risk of asthma (OR = 1.73, 95% CI = 0.98-3.00, p = 0.0524) and significantly associated with the presence of atopic comorbidities including AR and AD (all p < 0.05). Epitope mapping identified to 6 critical residues, K10, H35, R43, D106, R117 and R130, where alanine substitution led to a marked reduction in IgE binding (median reduction >95%). Conclusion: Der p 22 is a clinically relevant HDM allergen in the Malaysian adult population. It harbours both unique and shared IgE epitopes with Der p 2, highlighting its value for inclusion in molecular diagnostic panels to improve allergen sensitization profiling. Alanine mutation to 6 amino acid residues of Der p 22 significantly reduced IgE binding, suggesting its potential as a candidate hypoallergen molecule in allergen-specific immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.